|
|
Informationen über |
|
|
GlycoTech Corporation |
| Firmenart: Großmengen Chemikalien Produzent |
GlycoTech was founded in 1991 and remains today as one of the premier companies focusing on the biological functions and medical applications of glycoconjugates. The company has established its own research programs and has developed a large intellectual property portfolio. Through its catalog business, GlycoTech has also established one of the largest libraries of rare carbohydrate reagents and technologies worldwide.
GlycoTech has maintained a corporate alliance with Novartis for the past six years to develop small molecule mimics of carbohydrate ligands as potent antagonists for the aberrant extravasation of lymphocytes from the bloodstream during transplantation-induced reperfusion injury.
In addition, licensing agreements were recently established with Chiron Corporation for worldwide sales in cancer diagnostics using anti-carbohydrate tumor markers owned by GlycoTech.
Research agreements have also been established with the National Institutes of Health, the University of Pennsylvania, the University of Rochester, and the Chicago Institute for Neurosurgery and Neuroresearch.
GlycoTech is actively seeking other pharmaceutical partners and offers a combined range of expertise focusing on the Glycobiology area. The corporate structure and strategy of GlycoTech allows its partners to quickly obtain this unique expertise and avoid the obligations encountered with the fixed financial responsibilities associated with internal organic growth. We welcome the opportunity to meet with all interested parties to explore mutually constructive collaborations.
|
|
| Adresse |
GlycoTech Corporation
7860 Beechcraft Ave
Gaithersburg, Maryland 20879, USA
|
| Telefon |
+1 301 738-1080 |
| Fax |
+1 301 738-1077 |
| |
Email senden |
|
|
|
|
|
|
